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Innate immune activation is a major contributor to Alzheimer’s Disease (AD)
pathophysiology, although the mechanisms involved are poorly understood. Chemokine
C-C motif ligand (CCL) 2 is produced by neurons and glial cells and is upregulated
in the AD brain. Transgene expression of CCL2 in mouse models of amyloidosis
produces microglia-induced amyloid β oligomerization, a strong indication of the role
of these activation pathways in the amyloidogenic processes of AD. We have previously
shown that CCL2 polarizes microglia in wild type mice. However, how CCL2 signaling
contributes to tau pathogenesis remains unknown. To address this question, CCL2
was delivered via recombinant adeno-associated virus serotype 9 into both cortex and
hippocampus of a mouse model with tau pathology (rTg4510). We report that CCL2
overexpression aggravated tau pathology in rTg4510 as shown by the increase in
Gallyas stained neurofibrillary tangles as well as phosphorylated tau-positive inclusions.
In addition, biochemical analysis showed a reduction in the levels of detergent-soluble tau
species followed by increase in the insoluble fraction, indicating a shift toward larger tau
aggregates. Indeed, increased levels of high molecular weight species of phosphorylated
tau were found in the mice injected with CCL2. We also report that worsening of tau
pathology following CCL2 overexpression was accompanied by a distinct inflammatory
response. We report an increase in leukocyte common antigen (CD45) and Cluster of
differentiation 68 (CD68) expression in the brain of rTg4510 mice without altering the
expression levels of a cell-surface protein Transmembrane Protein 119 (Tmem119) and
ionized calcium-binding adaptor molecule 1 (Iba-1) in resident microglia. Furthermore,
the analysis of cytokines in brain extract showed a significant increase in interleukin (IL)-6
and CCL3, while CCL5 levels were decreased in CCL2 mice. No changes were observed
in IL-1α, IL-1β, TNF-α. IL-4, Vascular endothelial growth factor-VEGF, IL-13 and CCL11.
Joly-Amado et al. CCL2 and Tau Pathology
Taken together our data report for the first time that overexpression of CCL2 promotes
the increase of pathogenic tau species and is associated with glial neuroinflammatory
changes that are deleterious. We propose that these events may contribute to the
pathogenesis of Alzheimer’s disease and other tauopathies.
Keywords: monocyte chemoattractant protein-1 (MCP-1), neuroinflammation, Alzheimer’s disease, tau, Aβ, gene
therapy
INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative
disease, which is characterized by the formation of
extracellular amyloid plaques (or senile plaques) and
intracellular neurofibrillary tangles resulting from tau protein
hyperphosphorylation and aggregation. Glial and innate immune
activation are also hallmarks of AD although their contribution
to the etiopathology of the disease is unclear. Microglia, the
resident inflammatory cells of the brain, are found in a highly
activated state in the AD brain. Activation of microglia is
indicated by morphological alterations, proliferation, increased
expression of cell surface receptors, and secretion of cytokines
and chemokines (1). In AD, Aβ and tau pathology have been
shown to activate microglia both in vivo and in vitro (2).
Interestingly, microglial activation can precede the emergence
of amyloid or tau pathology in some mouse models (3, 4),
suggesting that it is an early event promoting Aβ and tau
pathologies. The CC-chemokine ligand 2 (CCL2), also known as
monocyte chemotactic protein-1 (MCP-1), is present in the brain
and produced by microglia, neurons, activated astrocytes, and
mononuclear phagocytes (5). CCL2 binds to the CC-chemokine
receptor 2 (CCR2) to regulate cell infiltration into peripheral
tissue and brain during infectious and inflammatory events
affecting disease processes (6–8). Data analysis of cytokines and
chemokines levels in brain tissue from AD patients revealed an
increase in CCL2 expression compared to age matched healthy
patients (9, 10). Interestingly, in brain tissue of AD patients,
CCL2 is present in neurons, astrocytes, reactive microglia,
as well as senile plaques and micro vessels (9–12). Further,
CCL2 levels in CSF (13) and plasma (14) correlates with a
faster cognitive decline in AD patients and in an asymptomatic
aging adult population (15). Thus, CCL2 seems to be a viable
candidate to glial activation in the neuropathology of AD and
other tauopathies.
Studies of CCL2 in animal models with amyloid deposition
have highlighted the role of CCL2 in the disease and
its contribution to AD pathology. In particular, it appears
that CCL2-signaling can exacerbate Aβ pathology in animal
models of AD. For instance, Yamamoto and colleagues have
demonstrated that the bigenic APP/CCL2 mice, overexpressing
CCL2 under the control of the human glial fibrillar acidic
protein (GFAP) promoter, displayed increased microgliosis and
astrogliosis, enhanced Aβ aggregation and amyloid plaques
with no alteration of APP processing when compared to
APP mice (16). The authors later reported hippocampal
synaptic dysfunction and worsening of memory impairment
in this model (17). Conversely, double mutant APP/PS1/CCL2
null mice also displayed increased levels of Aβ oligomers,
microglia accumulation around plaques, impaired neurogenesis
and worsening of cognitive dysfunction (18). Similarly, a total
deficiency in CCR2 precipitates Aβ accumulation by decreasing
Aβ clearance in APP mice (19) demonstrating the ambiguity of
the role of CCL2 on Aβ pathology.
Opposite results were however observed in a recent study
showing that total CCL2 deficiency in the 5xFAD amyloid
mouse model, improved cognition during Y-maze, normalized
IL-1β and CCL3 levels, reduced astrogliosis and amyloid plaque
formation as well as Aβ accumulation and neurodegeneration
(20). In parallel, reduction of microglia activation and Aβ
accumulation in APP/PS1 following genetic manipulations
correlated with decreased CCL2 in the brain (21) consistent
with Gutierrez’s findings. Although the mechanisms of action
of this dual role for CCL2 remain to be elucidated, it appears
clear that CCL2—CCR2 signaling contributes to Aβ pathology,
independently of an APP processing mechanism. However, the
studies investigating the role of CCL2—CCR2 pathway in tau
pathology are very scarce. Indeed, we could only find one report
relating the effects of CCR2 manipulation on tau pathology in
which genetic deletion of Ccr2 reduced traumatic lesions but
enhanced endogenous tau hyperphosphorylation in the brain of
a mouse model of traumatic brain injury (22). This emphasizes
the need for further studies elucidating the role of CCL2 in
tau pathology.
Toward this goal, we investigated the role of CCL2 cerebral
overexpression on glial activation and tau pathology in the
rTg4510 mouse model of tauopathy. We have previously shown
that overexpression of CCL2 through rAAV9 transduction
achieved glial activation in aged non-transgenic mice (23).
Therefore, overexpression of CCL2 or RFP via rAAV9-virus was
utilized to transduce anterior cerebral cortex and hippocampus
of 5-month-old rTg4510 tau mice. We report that CCL2
overexpression induced worsening in tau pathology by inducing
tau phosphorylation, increase in phosphorylated high molecular
tau species as well as insoluble tau. We also found that CCL2
induced microgliosis and changes in astrocytic morphogenesis
together with changes in inflammatory cytokines in the brain of
rTg4510 mice.
Altogether our data show for the first time that cerebral
overexpression of CCL2 facilitates tau accumulation together
with glial neuroinflammatory changes in a relevant mouse model
of tauopathy. Neuroinflammatory pathways and specifically
the CCL2—CCR2 axis could be determinant factors in
identifying new targets that aim at reducing the common
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All animal testing procedures were approved by the Institutional
Animal Care and Use Committee of the University of South
Florida and were performed in accordance with the eighth
edition of the “Guide for the Care and Use of Laboratory
Animals,” published by the National Academy of Science, the
National Academies Press, Washington, DC (2011).
The regulatable Tg4510 (rTg4510) mouse line was used
for this study. Parental mutant tau and tetracycline-controlled
transactivator (tTA) protein mouse lines were maintained
separately and bred to produce rTg4510, non-transgenic and
tTA only littermates as described previously (24). The rTg4510
mouse carries the P301L mutation (tetO-MAPT∗P301L), which
is associated with an autosomal dominantly inherited dementia
referred to as frontotemporal dementia and parkinsonism linked
to chromosome 17 (FTDP-17) (25). Although recent work
suggests that some of the Tg4510 phenotype may be due to
insertional mutagenesis events (26), this should not confound
comparisons of treatments within the rTg4510 line.
Transgenic APP/PS1 mice were obtained from a breeding
colony at the University of South Florida and have been
maintained for >20 years. This line has been shown to have a
selective increase in the level of Aβ42 as opposed to Aβ40 (27) and
to develop extracellular Aβ deposits, which increase in number,
size and density with aging (28). Mice were housed individually
and maintained on a 12-h light/dark cycle. Food (E2018, Envigo)
and water was given ad libitum
Experimental Design
Five-month-old rTg4510 mice balanced for sex underwent
intracranial bilateral injection of rAAV9-CCL2 (n = 6) or red
fluorescent protein (RFP, n= 6) in both the hippocampus and the
anterior cortex for a total of four injections. Twomonths after the
intracranial injections, brain tissue was collected.
To measure the effect of CCL2 overexpression on amyloid
pathology, a similar experiment was conducted on APP/PS1
mice. Twenty-month-old APP/PS1 mice received intracranial
bilateral injection of rAAV9-CCL2 (n = 10) or green fluorescent
protein (GFP, n = 10) in both the hippocampus and the anterior
cortex. Four months after intracranial injections, brain tissue
was collected.
For all animals and post-perfusion, half of the brain was
collected for histology and tissue from the other half of
the brain was dissected and utilized for western analysis or
multiplex assays as described below. Studies conducted at our
laboratory for almost one decade have demonstrated the efficacy
of recombinant adeno-associated virus (rAAV) serotype 9 to
transduce neurons within specific regions in the mouse brain
(29–32). rAAV9 drives robust gene expression as early as 1 week
in vitro and in vivo (33, 34) and persists for more than 9 months
in mouse brain (35). Therefore, rAAV9 is a preferred candidate
to deliver CCL2/RFP in vivo as previously reported (23). We
chose to examine neuroinflammation and tau pathology after
2–4 months of viral injection to allow strong expression and to
provide time for recovery from the intracranial injection.
CCL2/RFP-AAV9 Preparation
The CCL2/RFP clone was generated as previously described (23).
Briefly, mouse cDNA was amplified using PCR with primers
5′- GAGACCGGTCCACCATGCAGGTCCCTGTCATGCTTC-
3′ and 5′GAGGCTAGCCTAGTTCACTGTCACACTGGTCAC
TCC-3′. CCL2 was cloned into the AgeI and NheI sites of
the rAAV vector pTR2-RMCS under the control of the hybrid
cytomegalovirus chicken β-actin promoter. This vector also
expresses red fluorescent protein (RFP) under the control of
the thymidine kinase promoter and AAV2 terminal repeats.
rAAV serotype 9 virus was generated using pAAV9 and pXX6 in
HEK293 cells as described previously (23, 29).
Intracranial Injections
The injection procedures were performed using a convection-
enhanced delivery method described previously (29). Briefly,
mice were anesthetized with 1.5% isoflurane with oxygenation
and secured into a stereotactic apparatus. Five-mo.-old rTg4510
mice received bilateral injections of 2 µl of rAAV9-CCL2 (7 ×
10∧12 vector genomes (vg)/ml, n = 6) or 2 µl of rAAV9-RFP
(control, n = 6 × 10∧12 vg/ml, control, n = 6) into both cortex
and hippocampus. Twenty-mo.-old APP/PS1 mice received
bilateral injections of 2 µl of rAAV9-CCL2 (7 × 10∧12 vector
genomes (vg)/ml, n = 6) or 2 µl of rAAV9-GFP (control, n = 9
× 10∧12 vg/ml, control, n = 6). The coordinates of injection
were as follows: hippocampus (from bregma) anteroposterior
−2.7mm, lateral ±2.7mm, dorsoventral −3.0mm; cortex,
anteroposterior (from bregma) +2.2mm, lateral ±1.7mm,
dorsoventral −3.0mm. A microsyringe injector and controller
(Stoelting, Wood Dale, IL, USA) were used to inject 2 µl of the
virus at a constant rate of 2.5 µl/min in each placement. The
needle was kept in place for 1min after injection and then raised
slowly. Mice were allowed to recover for 2 months.
Tissue Collection
Mice were euthanized 2 (rTg4510 mice) or 4 (APP/PS1) months
after injection, at 7 or 24 months of age, with a solution
containing pentobarbital and phenytoin, then transcardially
perfused with 25ml of 0.9% normal saline solution. Brains
were collected immediately following perfusion. One hemisphere
was dissected and frozen for western blot analysis and the
second hemisphere was immersion fixed in 4% phosphate-
buffered paraformaldehyde for 24 h. The fixed hemispheres were
cryoprotected in successive incubations of 10, 20, and 30%
sucrose solutions for 24 h each. Subsequently, brains were frozen
on a cold stage and sectioned in the horizontal plan (25µm
thickness) on a sliding microtome and stored in Dulbecco’s
phosphate buffered saline with 10mM sodium azide solution
at 4◦C. Keeping one hemisphere for biochemistry and one
for histochemistry allows to perform both analyses on all the
animals (N = 6 per treatment group for western blot as well
as immunochemistry).
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Histopathology
Stereological principles were employed to select the sections
stained for each marker. Immunohistochemical procedural
methods were described (28). Six to eight sections per animal (N
= 6 per treatment group) were placed in a multi-sample staining
tray and endogenous peroxidase was blocked (10%methanol, 3%
H2O2 in phosphate buffered saline, 10mM NaPO4, 0.8%NaCl,
pH 7.4, PBS;30min). Tissue samples were permeabilized with
0.2% lysine, 1%Triton X-100 in PBS solution and incubated
overnight in primary antibody. The following primary antibodies
were used for immunohistochemistry: CCL2 (rat anti-CCL2;
R&D Systems, Minneapolis, MN, USA), CD45 (rat anti-mouse;
AbD Serotec, Raleigh, NC, USA), CD68 (Bio-Rad, Hercules,
CA), Iba-1 (Wako, Richmond, VA) anti-tau phosphorylated
at Ser396 (rabbit polyclonal, Anaspec, Fremont, CA), total
tau H150 (rabbit polyclonal, SantaCruz Biotechnology), anti-
tau phosphorylated at Ser202/Thr205 AT8 (Thermo scientific,
Waltham, MA), anti-Aβ (prepared by Paul Gottschall, UAMS,
Arkansas, USA). Sections were washed in PBS, and then
incubated in corresponding biotinylated secondary antibody
(Vector Laboratories, Burlingame, CA). The tissue was again
washed after 2 h and incubated with Vectastain R© Elite R© ABC kit
(Vector Laboratories, Burlingame, CA) for enzyme conjugation.
Finally, sections were stained using 0.05% diaminobenzidine,
0.5% nickel ammonium sulfate and 0.03% H2O2. Tissue sections
were mounted onto slides, dehydrated, cover slipped and
prepared for analysis.
Immunofluorescence labeling for GFAP (Abcam, Burlingame,
CA), Tmem119 (rabbit polyclonal, abcam, Cambridge, UK) and
Iba-1 (goat polyclonal, abcam, Cambridge, UK) was performed
as follows. After incubation with the primary antibody, the
free-floating sections were incubated for 2 h with corresponding
Alexa Fluor 488 or 647 fluorophore-coupled antibody (1:1,500;
Invitrogen, Grand Island, NY, USA). Possible lipofuscin artifacts
were quenched by treating slides with 3% Sudan Black B
stain as described previously (36). Sections were rinsed in
Dulbecco’s PBS and coverslipped with VECTASHIELD Vibrance
antifade mounting medium with or without 4′,6-diamidino-
2-phenylindole (Vector Laboratories). Gallya’s staining was
performed as described (37). Briefly, slides were treated with
5% periodic acid for 5min, washed with water, and incubated
sequentially in silver iodide (1min) and 0.5% acetic acid
(10min) solutions prior to being placed in developer solution
(2.5% sodium carbonate, 0.1% ammonium nitrate, 0.1% silver
nitrate, 1% tungstosilicic acid, 0.7% formaldehyde). Slides
were treated with 0.5% acetic acid to stop the reaction,
then incubated with 0.1% gold chloride and placed in 1%
sodium thiosulfate. Following a final wash in water, slides
were dehydrated and coverslipped. Congo red histology was
performed as described (38). Briefly, 2.5mM NaOH was added
to a saturated sodium chloride-ethanol solution, and slides
were incubated for 20min. Subsequently, slides were incubated
in 0.2% Congo red in alkaline alcoholic saturated sodium
chloride solution for 30min. Slides were rinsed through 3
changes of 100% ethanol, cleared through 3 changes of xylene,
and coverslipped with Di-N-butyl phthalate in xylene (DPX;
VWR, vwr.com).
Tissue Imaging and Quantification
Immuno-labeled sections were imaged using a Zeiss Axio Scan
Z1 digital slide scanner at various magnification as indicated in
each figure legend. Digital images of each slide and its sections
were analyzed for threshold-defined pixel-positive area fraction
using custom-designed image analysis software (Nearcyte, Zeiss).
Values for all sections from the same mouse were averaged to
represent a single value for that region in subsequent statistical
analysis. For all analyses, an investigator blinded to the study
conditions captured the hippocampi for each animal (N = 6, 8
section per animal).
Immunofluorescent labeled sections were imaged using a
Nikon C2Plus Confocal Microscope. Representative images of
the Tmem119 and Iba-1 microglia positive surfaces were capture
using galvano-sequential scanning and 60x magnification was
captured using the z-stack feature (1.2 AU pinhole, 50 nm pixel
size) in NIS-Elements AR 5.11.01 software. For co-localization
analysis, Mander’s overlap coefficient was preferred over Pearson
correlation coefficient, to avoid differences in fluorescence
intensities between both antigens and the auto-background (39).
Sholl Analysis
To measure the astrocytic arborization we performed Sholl
analysis of GFAP positive astrocytes using the Fiji plug-in
for ImageJ (http://fiji.sc/Sholl_Analysis) following previously
published analysis protocol (40). Briefly, individual cells with
maximum projection were analyzed using fluorescence imaging
(16-bit greyscale). Images were adjusted to the brightness and
contrast threshold as indicated in the analysis software. A line
was drawn manually from the soma of astrocytes to the end of
its arbors to ensure maximum intersection points per cell. The
radius of 50µm was kept constant for each cell analyzed within
the region of interest (ROI). From the tiled 2D images of the
cortex the morphology of selected astrocytes was isolated. Sholl
analysis software was used to retrieve the cellular metrics. The
number of intersections from the output data were graphed using
GraphPad Prism 8.03.
Western Blotting
Tissues for Western blot analysis were prepared as previously
described (41). Dissected hippocampi (HPC) were homogenized
then sonicated in radio-immunoprecipitation assay (RIPA)
buffer containing protease inhibitor cocktail (Sigma Aldrich) and
phosphatase inhibitor cocktails I and II (Sigma Aldrich) and
centrifuged at 40,000 x G for 30min at 4◦C. The supernatant
was collected, and protein concentrations were determined by
the BCA protein assay kit (Pierce, Rockford, IL). The remaining
pellet was dissolved with 70% formic acid according to the
wet tissue weight, and then neutralized with NaOH to analyze
RIPA-soluble proteins. Equal amounts of proteins according to
BCA (5 µg/well for soluble fraction, 1 µg/well for insoluble
fraction) were loaded in each well of a 4–12% Bis-tris gels and
transferred to a 0.2µm pore size nitrocellulose membrane and
immunoblotted with H150 (Santacruz Biotechnology, Dallas,
TX), pSer396 tau (Anaspec, Fremont, CA), PHF1 (Fisher
Scientific, Waltham, MA), AT180 (Fisher Scientific, Waltham,
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MA) and pSer199/202 tau (Anaspec, Fremont, CA) at 1:1,000-
fold dilution. Band intensities at the 55 and 64 kDa range were
quantified by densitometric analysis using AlphaEase software
(Alpha Innoch, CA, USA) and normalized to the band intensity
of GAPDH (for RIPA soluble fraction) and total protein (RIPA
insoluble fraction).
Multiplex Chemokine/Cytokine Assay
Snap-frozen right hippocampi from all the animals were
homogenized in RIPA buffer (50mM Tris, pH 7.5, 150mM
NaCl, 1mM ethylene diamine tetra-acetic acid, 1% Triton
X-100, protease inhibitor cocktail and phosphatase inhibitor
cocktail I and II; Sigma). The protein concentration of each
sample was measured using the Bradford protein assay (Bio-
Rad Laboratories, Hercules, CA, USA) and adjusted to 4.5
mg/ml. The concentrations of Interleukin-6, C-C motif ligand 3
(CCL3), Interleukin 1 alpha (IL-1α), C-C motif ligand 5 (CCL5),
Tumor Necrosis Factor-alpha (TNF-α), Interleukin 1 beta (IL-
1β), Interleukin 10 (IL-10), Interleukin 13 (IL-13), Vascular
endothelial growth factor (VEGF), KC, C-C motif ligand 11
(CCL11), Interferon-gamma (IFN-γ), and Interleukin 4 (IL-
4) were measured using the mouse cytokine/chemokine panel
(MILLIPLEX MAP kit; Millipore, Billerica, MA, USA) according
to the manufacturer’s protocol. In brief, the Bio-Plex Suspension
Array System (Bio-Rad Laboratories) was calibrated using CAL2
with the high PMT setting of the Bio-Plex calibration kit,
and standard sample preparation was performed according to
the manufacturer’s directions. The filter plate was pre-wetted
with wash buffer and vacuum-filtered before adding standard,
control or study samples to the appropriate wells. Mixed capture
beads were then added to each well, and plates were incubated
overnight at 4◦C with shaking. After two washes, 25 µl of
detection antibody was added to each well, incubated for 1 h at
room temperature and then treated with 25 µl of streptavidin-
phycoerythrin for 30min at room temperature. The plate was
washed twice, and 150 µl of the Bio-Plex sheath fluid assay
buffer were added to each well and read using the Bio-Plex
Suspension Array System software (Bio-Rad Laboratories) per
the kit instructions. The concentration of each analyte was
calculated according to the standard curve.
Statistical Analysis
For each genotype (either rTg4510 or APP/PS1), statistical
analyses were performed using Student’s t-test followed by
Fisher’s least significant difference post hoc means comparison.
For cytokine analysis, multiple t-test analysis was performed
without assuming a consistent SD (df = N−2) and followed
by post-hoc correction. Statistical analysis and graphs were
generated using GraphPad Prism 8.03 software (GraphPad
Software, La Jolla, CA, USA).
RESULTS
Intracranial Injection of AAV9- CCL2
Induced Strong Expression of CCL2
Overexpression of CCL2 was confirmed by
immunohistochemical analysis (Figure 1). We demonstrate
that rAAV9-CCL2 injected mice present increased CCL2
expression (Figure 1D) localized to injected areas i.e., cortex
(Figure 1E) and hippocampus (Figure 1F). As expected, no
CCL2 signal was detected in the rAAV9-RFP injected control
mice (Figures 1A–C). Quantitation of area positively stained for
CCL2 showed a significant increase of CCL2 expression in both
cortex and hippocampus but not in synaptically connected areas
such as the entorhinal cortex, when compared to rAAV-RFP
(Figure 1G).
Quantitation of CCL2 protein levels in hippocampal tissue
was performed by using the MILLIPLEX MAP Multi-plex assay
kit (Figure 1H). Basal levels of CCL2 in rAAV9-RFP-injected
animals were in the low range (0.52 ± 0.1 ng/mg of protein);
however, as expected, CCL2 expression was significantly higher
in the hippocampus of rAAV9-CCL2-injected animals (10.1 ±
0.2 ng/mg of protein) resulting in a 20-fold increase when
compared to rAAV9-RFP-injected control animals (Figure 1H).
The CCL2 levels measured here are in range to what was
previously reported in the hippocampus of non-transgenic
mice challenged with LPS (42, 43), suggesting that the ng
range of CCL2 protein is required to maintain a prolonged
inflammatory state during brain injury. We demonstrated
that brain overexpression of CCL2 achieved through AAV9-
transduciton was sustained 2 months after surgery.
Overexpression of CCL2 in the Brain of
rTg4510 Did Not Change Microglia Density
but Resulted in Microglia Activation
We first assessed the effect of CCL2 overexpression on
microglial abundance in rTg4510. Brain tissue was examined
for microglial pan-marker Iba-1 immunoreactivity in rAAV9-
RFP (Figures 2A,C) and rAAV9-CCL2 (Figures 2B,D) injected
rTg4510 mice. Quantification analysis of Iba-1 positive area
stained (Figure 2E) in cortical areas (Figure 2E, ACX, EC) and
hippocampus (Figure 2E, HPC) revealed no difference in Iba-
1 levels between CCL2 treated mice and RFP control mice.
Similarly, levels of Iba-1+ positive meningeal macrophages
remained similar between rAAV9-CCL2 mice and rAAV9-RFP
expressing mice (Figures 2C,D,E, MNG).
To further characterize the microglia activation profile
following CCL2 overexpression, immunoreactivity of brain
tissue for CD45 microglia was measured in rAAV9-RFP
(Figure 3A) and rAAV9-CCL2 injected rTg4510 mice
(Figure 3B). Quantitation of the positive area stained for
CD45 using image analysis revealed significant increases in
CD45 levels in anterior cortex (ACX), hippocampus (HPC)
and entorhinal cortex (EC) of CCL2 overexpressing mice when
compared to rAAV9-RFP control mice (Figure 3E). Similarly,
immunohistochemical analysis for CD68 positive phagocytic
microglia was performed (Figures 3C,D). Analysis of CD68
positive area revealed significantly increased levels of phagocytic
microglia in the injected hippocampus (HPC), and connected
regions, entorhinal cortex (EC), of rAAV9-CCL2 injected
rTg4510 mice when compared to RFP injected littermates
(Figure 3F). Although we found a trend toward increased CD68
levels in the anterior cortex of rAAV9-CCL2 when compared
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FIGURE 1 | Intracranial injections of AAV9-RFP or AAV9-CCL2 in cortex and hippocampus in rTg4510 mice. Five-mo-old rTg4510 mice underwent intracranial
bilateral injection of rAAV9-CCL2 (n = 6) or red fluorescent protein (RFP, n = 6) in both the hippocampus and the anterior cortex. Two months after the intracranial
injections, brain tissue was collected. Micrographs represent the immunohistochemistry staining for CCL2 in RFP injected (A–C) and CCL2- injected animals (D–F).
Higher magnification shows cell localization of CCL2 (insets). (G) Percent positive area of distribution in anterior cortex (ACX, boxed area), hippocampus (DG and CA3,
boxed area) and entorhinal cortex (EC) of injected animals (n = 6, **p < 0.01 and ***p < 0.001). (H) CCL2 levels were measured in the hippocampus of injected mice
by multiplex assay and the results were normalized to the amount of protein (ng/mg of protein). Student’s t-test were performed between RFP and CCL2 groups for
each dependent variable and each brain region separately. Scale bar represents 1,000µm in (A,D), 200µm in (B,C,E,F) and 20µm in insets.
to RFP injected mice, the difference did not reach significance
(Figure 3F). It is recognized that staining for CD45 or CD68
cannot unambiguously discriminate intrinsic microglia from
recruited myeloid linage cells. Recently, it has been suggested
that infiltrating macrophages in the brain can be discriminated
based on their expression of Iba-1 and lack of co-localization
with Tmem119, a highly expressed microglia-specific marker of
resident microglia (44). Thus, to further dissect the microglia-
specific response to CCL2, we performed immunofluorescence
labeling between Iba-1 and Tmem119 and examined the relative
expression of both markers (Figure 4). We observed no mean
fluorescence intensity (MFI) difference between RFP and CCL2
in Tmem119+ and Iba-1+ microglia, suggesting that CCL2
did not affect the overall relative expression and/or microglia
abundance (Figures 4A,B,E,F). High magnification imaging and
z-stack image analyses demonstrated overlap of Tmem119+
with Iba-1+ relative intensity in both RFP- and CCL2-injected
mice (Figures 4I,J,L,M). Further analysis of immunolocalization
using Mander’s overlap coefficient showed 0.89- and 0.91-pixel
value average for RFP- and CCL2 -injected mice, respectively
(Figures 4K,N), indicating that more of 90% of the Iba-1+ cells
were enriched for Tmem119 immunoreactivity. Taken together,
these findings suggest that albeit CCL2 did not increase the
relative levels of Tmem119+/Iba-1+ intrinsic microglia, its
overexpression had a vast impact on activation of CD45 and
CD68 phagocytic microglia in the brain of rTg4510 mice.
Overexpression of CCL2 in the Brain of
rTg4510 Induced Astrocytic Dendritic
Arborization
Astrogliosis was measured via the immunoreactivity levels of
glial fibrillary acidic protein (GFAP), an intermediate filament
(IF) protein that is highly specific marker for the astrocytic
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FIGURE 2 | CCL2 overexpression does not affect microglia abundance in rTg4510. Micrograph representation of hippocampal area (A,B) and cortical area (C,D)
stained for Iba-1 in RFP injected animals (A,C) and CCL2 injected animals (B,D). Quantification of positive area stained is presented for anterior cortex (ACX),
hippocampus (HPC) entorhinal cortex (EC) and meninges (MNG) for Iba-1 (mean ± S.E.M, n = 6) (E). Student’s t-test were prformed between RFP and CCL2 groups
for each dependent variable and each brain region separately (n = 6). The scale bar represents 50µm in panels and 20µm in insets. Meningeal area is outlined in the
cortical images (C,D, m).
cells in the brain (45) (Figure 5). Images from fluorescence
immunohistochemical stain of astrocytes (GFAP, green) are
shown following CCL2 expression in rTg4510 mice compared
to RFP injected littermates (Figures 5A,B). Comparably to our
observations on Iba-1, we found that GFAP immunoreactivity
remained unchanged between groups, as represented by the
quantification of positive area stained for GFAP in anterior
cortex (Figure 5E, ACX). However, this finding does not
account for the vast morphological changes of the astrocytes
following CCL2 expression. This prompted us to perform Sholl
analysis of the dendritic arbor complexity of GFAP positive
astrocytes in the cortices of AAV9-CCL2 vs. AAV9-RFP mice
(Figures 5B,D). We showed that astrocytic arborization in
CCL2 mice was significantly increased compared to that of
astrocytes from control mice (Figures 5A,C), as identified by the
increased number of intersections per given astrocyte at a fixed
distance from soma (Figures 5F,G). These results indicate that
enhanced dendritic development occurred in astrocytes upon
overexpression of CCL2 in rTg4510 mice.
AAV9-Mediated CCL2 Overexpression
Induced Changes in Levels of Cytokines
Associated With Neuroinflammation
We have previously reported the impact of CCL2 on microglia
polarization in wild-type mice (23, 46). Therefore, we aimed
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FIGURE 3 | CCL2 overexpression induces microglia activation in rTg4510 brain. Micrograph representation of cortical area stained for CD45 and CD68 in RFP
injected animals (A,C) and CCL2 injected animals (B,D). Quantification of positive area stained is presented for anterior cortex (ACX), hippocampus (HPC) and
entorhinal cortex (EC) for CD45 (E) and CD68 (F) (mean ± S.E.M, n = 6). Student’s t-test were performed between RFP and CCL2 groups for each dependent
variable and each brain region separately (n = 6, *p < 0.05, **p < 0.01). The scale bar represents 200 and 20µm in panels and insets, respectively.
to investigate the effect of CCL2 on expression levels of a
range of cytokines in a tau animal model. Hippocampi from
rAAV9-CCL2- and rAAV9-RFP -injected rTg4510 mice were
homogenized and chemokines were measured using multiplex
assay (Millipore, Billerica, MA). We observed 1.5-fold increases
in the levels of IL-6 and CCL3 (Figure 6), in the hippocampi of
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FIGURE 4 | Tmem119 is stably expressed and co-localizes with Iba-1+ microglia in rTg4510 mice. Imaging of fluorescence labeled microglia with (A,E) Tmem119
(green) and (B,F) Iba-1 (purple) in the hippocampus of RFP- and CCL2-injected rTg4510 mice. Nuclei is stained with DAPI (C,G). Merged images of Tmem119 and
Iba1 immunoreactivity in brain sections from treated mice (D,H). N = 6, 8 section per animal. Scale bar, 100µm (I,J,L,M). High magnification (60x) co-localization
images utilizing z-stack image intensity of highly ramified Tmem119+ cells and Iba-1+ microglia. Scale bar, 10µm. (K,N) The intensity correlation analysis represented
by the scatter plots of the fluorescence intensities of Tmem119 (Alexa Fluor 488) and Iba-1 (Alexa Fluor 647) of confocal z-stacks. The degree of co-localization is
estimated by Mander’s overlap coefficient.
CCL2- compared to RFP-injected mice (49.9± 1.9 vs. 18.0± 9.4
pg/ml and 4.5 ± 0.4 pg/ml vs. 3.3 ± 0.3 ng/ml, respectively). In
addition, CCL5 levels were significantly decreased in response
to CCL2 overexpression (0.4 ± 0.2 vs. 7.2 ± 3.6 ng/ml in
CCL2-injected animals vs. RFP control animals, respectively). No
significant changes were observed in, IL-1α, TNF-α, IL-1β, IL-10,
IL-13, VGEF, KC, and CCL11 cerebral levels, while levels of IFN-
γ and IL-4 were undetectable. Interestingly, low nanogram range
of IL-12 levels were measured in RFP injected control mice (0.2±
0.1 ng/ml) but were undetectable in CCL2-injected animals (data
not shown). We conclude that CCL2 overexpression in tau mice
produced a unique pattern of inflammatory signals.
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FIGURE 5 | CCL2 induces astrocytic ramification in rTg4510 mice. (A) Images of fluorescence immunohistochemical stain of astrocytes (GFAP, green) in the cortices
of rTg4510 mice following CCL2 and (B) RFP overexpression. Individual astrocytes were subjected to Sholl analysis (box inset). (C,D) Maximum intensity projection of
each cell tiled micrographs extracting 2D images of astrocytes. Sholl-based metrics of arborization using a 50µm radii area from the soma of each astrocyte
measured the number of intersections. (E) Quantification of positive area stained for GFAP is presented for anterior cortex (ACX). (F) Sholl analysis retrieved
curve-fitting and regression analysis of astrocytes within the region of interest, demonstrated induced astrocytic intersection in CCL2 overexpressing mice compared
to the RFP mice. (G) Scattered plot of the number of astrocytic intersections in each group, Student t-test, Mann-Whitney unpaired parametric test, ****p < 0.0001.
Brain CCL2 Overexpression Aggravated
Tau Pathology
Next, we assessed the effect of CCL2 overexpression on tau
pathology, including immunoreactivity of brain tissue for
phosphorylated tau (p-tau) isoforms and neurofibrillary tangle
burden, in rAAV9-CCL2 and rAAV9-RFP injected rTg4510mice.
Micrograph representation of immunostaining in anterior cortex
(ACX) is shown for H150 (total tau (H150), Figures 7A,B),
AT8 (pSer199/Thr205, Figures 7C,D), pSer396 (Figures 7E,F) as
well as Gallyas staining (neurofibrillary tangles, Figures 7G,H).
Quantitation of positive area stained revealed a significant
increase in total tau levels in ACX and hippocampus (HPC) as
measured by the H150 antibody (Figure 7I). Interestingly, AT8
p-tau levels were significantly increased in both injected regions
(ACX/HPC) and synaptically connected entorhinal cortex (EC)
of CCL2 mice (Figure 7J). The pSer396 tau levels were also
significantly increased in HPC but not in ACX or EC of CCL2
mice (Figure 7K). Of note, we also observed a significant increase
in Gallyas staining in the ACX and EC, while a trend toward
increased tau burden was achieved in the HPC region (p = 0.08)
of CCL2 mice when compared to RFP injected control mice
(Figure 7L).
Biochemical analysis was performed to distinguish between
detergent soluble and insoluble tau levels in the brain. Western
blots were analyzed for levels of total tau (H150), and p-tau
epitopes (AT180, paired helical filaments 1: PHF-1, pSer199/202,
and pSer396) in the soluble fraction (Figures 8A,C) and in
the insoluble fraction (Figures 8B,D) of hippocampal brain
extracts of injected mice. Band pixel densitometry values were
normalized to GAPDH and then represented as the percentage
of controls. We found a significant increase in total tau levels
(H150, 55-64 kDa band) in the soluble fraction, while AT180
and PHF-1 p-tau levels were significantly decreased following
CCL2 overexpression (Figure 8C). No changes were observed in
pSer199/202 or pS396 p-tau levels in this fraction. However, we
observed a significant increase in pSer199/202 but not pSer396
high molecular weight band (140–150 kDa) intensity in the
soluble fraction (Figure 8C, HMW). No signal was detected for
highmolecular weight of H150, AT180, and PHF-1. Interestingly,
our analysis revealed significant increases in insoluble total tau
(H150), PHF-1 and pSer396 p-tau levels (55–64 kDa, Figure 8D),
while no changes were observed in pSer199/202 or AT180 p-
tau. Consistent with the worsening of tau pathology observed
by immunostaining, western blot analysis revealed a shift in
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FIGURE 6 | Cytokine levels following expression of CCL2 in rTg4510 mice.
The concentrations of Interleukin 1 alpha (IL-1α), Interleukin 1 beta (IL-1β),
Interleukin 6 (IL-6), Interleukin 10 (IL-10), Interleukin 13 (IL-13), C-C motif
ligand 11 (CCL11), Keratinocyte chemoattractant (KC), C-C motif ligand 3
(CCL3), C-C motif ligand 5 (CCL5), Vascular endothelial growth factor (VEGF)
and Tumor necrosis factor alpha (TNF-α) were measured using the mouse
cytokine/chemokine panel (MILLIPLEX MAP kit; Millipore, Billerica, MA, USA) in
CCL2 injected mice and RFP controls. (mean ± S.E.M, n = 6). Statistical
analysis was performed using multiple t-test analysis (*p < 0.05) with alpha =
0.05. and without assuming a consistent SD (df = N−2) followed by
post-hoc test.
tau solubility following CCL2 overexpression, where an increase
in total tau in all fractions reflected a decrease in soluble tau
forms while increasing levels of certain insoluble tau forms in
CCL2 mice.
Interestingly a similar shift from soluble to insoluble species
was observed in CCL2-overexpressing APP/PS1 mice. Indeed,
we observed a decrease in β-amyloid immuno-positive area in
the cortex of APP/PS1 mice (Figures 9A,B,E), while an increase
in amyloid plaque burden positive for Congo red was evident
in the same region compared to RFP-injected APP/PS1 mice
(Figures 9C,D,F).
DISCUSSION
This study shows for the first time a role of CCL2 overexpression
in exacerbation of tau pathology in rTg4510 mouse model,
associated with enhanced glial cells activation and changes
in inflammatory markers. Indeed, aggravated tau pathology
following CCL2 expression was observed as an overall increase
in total tau levels in the hippocampus independently of soluble
or insoluble fractions. Interestingly we observed a redistribution
of some of the p-tau epitopes toward increased aggregation state.
We detected a decrease in the soluble fraction of AT180 and
PHF1 p-tau species while the same species were increased in the
insoluble fraction. High molecular weight tau species were also
increased together with increased Gallyas positive neurofibrillary
tangles following CCL2 expression.
We also report that worsening of tau pathology was
associated with microglia activation and inflammatory response.
We have previously shown that CCL2 overexpression in the
brain of non-transgenic mice specifically increased microglia
polarization as well as induced extravasation of peripheral
myeloid-derived cells (CD45 positive) (23). In the present
study, unchanged immunoreactivity for Iba-1 microglia was
found in CCL2 injected rTg4510 mice when compared to
RFP-injected transgenic littermates, reflecting no difference in
microglia abundance. However, we observed enhanced microglia
activation determined by increased levels of CD45 and CD68
staining in CCL2 injected rTg4510 mice when compared to RFP-
injected transgenic littermates. As CD45 and CD68 are common
markers of both intrinsic microglia and recruited myeloid
lineage cells, we further investigated the origin of the Iba-1+
cells in the present study, by immunofluorescence labeling
with microglia specific marker, Tmem119 (44). We report that
approximately 90% of the Tmem119+ cells overlapped with
Iba-1+ cells across the study, suggesting that overexpression of
CCL2 had no effect on the overall levels of Tmem119+/Iba-1+
resident microglia in rTg4510 mouse models. In addition, Sholl
quantification of astrocytic complexity found significant increase
in astrocytic arborization of CCL2 mice compared to control
mice, suggestive of astrocyte activation. In a similar fashion to
that observed in microglia, CCL2 overexpression in rTg4510 was
not associated with increased astrocytic density but increased
astrocytic dendritic development. Further future experiments are
required to establish the role of CCL2 in astrocytic architechture
and activation.
Previous findings from our laboratory and others have
demonstrated microglia activation and inflammatory profile
in response to pathological tau in rTg4510 mice (47), as
indicated by high immunoreactivity of Iba-1, CD45 and GFAP
(37, 41, 48, 49) when compared to age-matched non-transgenic
littermates. This inflammatory profile seems to vary with age
in rTg4510 (37, 48) and to be tau dependent as it was reversed
by suppression of the tau transgene expression (48, 49). In a
similar fashion, we and others have reported elevation of CD45
and CD68 microglia levels and increased pathology in rTg4510
mouse model following neuroinflammatory manipulations.
Indeed, cerebral LPS injection resulted in increased CD45
and Ym1 immunoreactivity, which was associated with
increased tau phosphorylation without changes in total tau
levels or tau tangle formation. Similarly, mice deficient for
fractalkine where characterized by increased CD45 and CD68
levels as well as worsening in tau pathology (50). In contrast,
fractalkine overexpression was associated with decreased
levels of CD45 microglia and tau pathology (51). In studies
involving neuroinflammatory manipulations in mice model
of proteinopathies, deciphering whether microglia activation
is a cause, or a consequence of increased pathology remains
challenging. To the same extend, the exact mechanism on how
CCL2 contributes to tau pathology was not fully elaborated
here. One of the limitations in our study is the ability to
discriminate the effects of CCL2 on infiltration of peripheral
cells and their subsequent effect on tau pathology. Indeed, BBB
breakdown induced by disruption of adherents junctions in
response to CCL2 has been evidenced (52) and could play a
role in worsening of tau pathology by facilitating, for instance,
Frontiers in Immunology | www.frontiersin.org 11 May 2020 | Volume 11 | Article 997
Joly-Amado et al. CCL2 and Tau Pathology
FIGURE 7 | CCL2 overexpression induces tau accumulation in rTg4510 mice. Images of immunostaining in the cortical area for H150 tau (A,B), p-tau AT8 (C,D) and
pSer396 (E,F) as well as Gallyas staining (aggregated tau G,H) in mice injected with either rAAV9-RFP or rAAV9-CCL2. Quantification of positive area stained is shown
in anterior cortex (ACX), hippocampus (HPC), entorhinal cortex (EC) for total tau H150 (I), p-tau AT8 (J), pSer396 (K) and Gallyas (L). Scale bar represents 100 and
20µm. Statistical analysis by Student t-test (n = 6, *p < 0.05, **p < 0.01, ***p < 0.001).
leucocyte transmigration into the brain. We also can’t exclude
the possibility of a third and unrelated mechanism that could
link CCL2 to induced tauopathy, while microglia activation is a
by-product of tau pathology worsening. Together with the role
of CCL2 described in the literature and our previous reported
findings (23), our current findings suggest that CCL2 increased
microglial and astrocytic activation following overexpression and
was associated with worsening of tau pathology in rTg4510 mice.
To further assess the inflammatory profile associated with
CCL2 overexpression in rTg4510, we measured a panel of
different cytokines spanning along the inflammatory activation
scale. Here, we report that increase in CCL2 was accompanied
by increased levels of cytokines IL-6 and CCL3. These cytokines
have been shown to be produced by glial cells in vitro (53)
and in vivo (54). Therefore, we suggest that activated glial cells
are the major source of the measured cytokine levels following
CCL2 overexpression. Interestingly, the meningeal infiltrated T
cells can also secrete cytokines and maintain the homeostatic
cytokine profile in the brain (55). Although not measured in this
study, our group has reported that impaired blood brain barrier
and T-cell, red blood cell and immunoglobuline infiltration
was evident in rTg4510 mouse model as early as 9 months
of age (49). Despite as much as 60% of the meningeal area
displaying Iba-1 immunoreactivity, we found that CCL2 did not
increase the abundance and Iba-1+ positive immune cells in
the meninges. This could be due to other underlying aberrant
processes implicating different immune cells infiltration in this
model as disscused above.
Additionally, we report that CCL2 overexpression resulted
in increased IL-6 production in the hippocampus. Altered IL-6
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FIGURE 8 | CCL2 overexpression worsens tau pathology in rTg4510 mice. Western blots analyses of total tau (H150), and p-tau (AT180, PHF1, pSer396, and
pSer199/202) in the soluble hippocampal brain fraction (A) and insoluble fraction (B). Band pixel densitometry values normalized to GAPDH and control mice for
soluble fraction (C), and to controls for insoluble fraction (D) (n = 6, *p < 0.05, **p < 0.01, Student t-test). Overall, CCL2 overexpression resulted in increased high
molecular weight tau in soluble fractions together with increased intensity of phosphorylated epitopes in insoluble fractions.
expression is found in CSF and around amyloid plaques in the
brain of Alzheimer’s disease (AD) patients (56, 57). In particular,
IL-6 stimulates the production of APP in neurons in vitro (58),
while cultured glial cells stimulated with APP can trigger IL-6
production (53). Moreover, IL-6 also enhances neuronal damage
induced by Aβ peptide in cultured rat cortical neurons (59). A
direct link between increased IL-6 and tau phosphorylation was
established in vitro. Indeed, IL-6 administration in rat neurons
led to an increase in p-tau species but not total tau, through
activation of JAK/STAT andMAPK-p38 (60). IL-6 and CCL2 can
induce each other and cooperatively elicit chemoattraction and
recruitment of activated immune cells in a positive feedback loop
to maintain and amplify a proinflammatory-like profile (61–63).
Further analysis would be necessary to consider whether a similar
pathway was involved in the worsening of tau pathology observed
in the present study.
We also report that CCL2 overexpression in rTg4510
was associated with an increase in CCL3 production in the
hippocampus. CCL3 is a chemokine involved in chemotaxis
and has been shown to contribute to T cell recruitment to the
brain (64, 65). In accordance with our data, increased CCL3
production by microglial cells was observed in a different model
of tauopathy, THY-Tau22 mice (54). The authors report that
CCL3 induced the recruitment of T-cells into the hippocampus
through chemotaxis, which promoted tau pathology in this
model. T-cell infiltration has been previously demonstrated in
older (12 months old) rTg4510 mice and was associated with
a leaky blood-brain barrier (49). Albeit not investigated in
this study, the possibility of a leaky BBB at this age together
with the induction of IL-6 and chemotactic CCL3 and CCL2
signaling could suggest that aggravated tau pathology is a result of
downstream events resulting from a plethora of infiltrated cells,
including T-cell leucocytes.
More investigation of the role of CCL2 on tau pathology
is needed to further understand the possible relationship
between CCL2 signaling and tau burden. In fact, the role of
CCL2 in AD has been studied more extensively in amyloid
β animal models of AD than in tauopathies and have led
to contradictory findings. Indeed, genetic manipulations of
CCL2 in a mouse model of amyloidosis led to the worsening
of Aβ pathology with both overexpression and deficiency in
CCL2. Moreover, overexpression of CCL2 driven by GFAP
promoter in APP/CCL2 mice enhanced amyloidosis, increased
microglial Iba-1immunoreactivity, and decreased cognition (16,
17) while APP/PS1/CCL2 null mice also displayed increased
levels of Aβ oligomers and worsening of cognitive dysfunction
(18). The authors hypothesized that two different mechanisms
could be involved, namely overexpression of CCL2 might
promote Aβ assembly and microglial activation, whereas a
deficiency in CCL2 would impair phagocytosis and clearance
of Aβ (18). Our present findings support an increase in
amyloidosis following CCL2 overexpression in the brain of
APP/PS1 mice. Moreover, we found a decrease in soluble β-
amyloid, that was redistributed toward amyloid plaque burden
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FIGURE 9 | Amyloidosis following CCL2 overexpression in APP/PS1 mice. Micrograph representation of cortical area stained for amyloid beta (Aβ, A,B) and Congo
red (C,D) in GFP injected animals (A,C) and CCL2 injected animals (B,D). Quantification of positive area stained is presented for anterior cortex amyloid beta (E) and
Congo red (F) (Avg ± S.E.M, n = 10). Statistical analysis was performed using Student’s t-test (n = 6, *p < 0.05) followed by Fisher’s PLSD multiple comparison test.
Scale bar represents 200µm and insets represent 20µm.
following 4 months of CCL2 expression, similar to what was
observed with tau pathology in rTg4510 mice. In agreement,
a disruption of CCL2 signaling through deficiency in CCL2
receptor in APP/CCR2 null mice precipitates Aβ accumulation
by decreasing Aβ clearance in APP mice (19). However,
a recent report showed improved cognition and decreased
amyloidosis in 5xFAD/CCL2 null mice, another amyloid mouse
model (20). Decrease in pathology was associated with a
decrease in GFAP immunoreactivity in these mice, while control
CCL2 null mice displayed an increase in IL-1β and GFAP
immunoreactivity compared to non-transgenic mice. Altogether,
these reports suggest that CCL2 action and signaling depend
on the inflammatory milieu of the animal models employed
and could lead to beneficial as well as detrimental responses.
Another interesting report suggests that a gradient in CCL2 is
required for its chemotactic capacity [reviewed in (66)]. Thus,
it is possible that basal levels of CCL2 are required for brain
homeostasis and therefore deficiency or overexpression would
lead to detrimental effects on neuroinflammation. These dual
effects of microglia are in accordance with the hypothesis of
a dual peak of microglia activation in Alzheimer’s trajectory
recently advanced, which describes an early protective peak
and a later pro-inflammatory peak in Alzheimer’s disease
pathophysiology (67). The contradictory results observed in AD
models could be consequently explained by different stages of the
diseases at the time of the experiment. Future studies involving
neuroinflammation modulation should consider testing different
time points of the disease stage. Identifying molecules with a
pivotal role in determining the detrimental or beneficial effects
of microglia is also important.
Altogether our results demonstrate an increase in tau
accumulation following CCL2 overexpression in the rTg4510
mouse model of tauopathy together with glia activation,
ultimately changing the neuroinflammation milieu. Given the
contradictory results observed in mouse models of amyloidosis,
more studies involving the role of CCL2 signaling concerning
tau pathology are needed. Moreover, the degree of pathological
insult and stage of the disease; i.e., Braak staging should be taken
into consideration for translational relevance. Nevertheless,
this is the first report linking directly CCL2 overexpression
with increased tau pathology, providing important new anti-
inflammatory avenues for future therapeutic intervention in AD
and related tauopathies.
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